Patent ID: 6258849
Filing Date: 2001-07-10
Classification: A61K,A61P

Abstract:
A pharmaceutical composition, comprising in solution: a compound of Formula I: ##STR10##wherein n is 0, 1, 2, 3, 4, or 5; M is hydrogen, a salt forming cation, an alkyl (C.sub.1-6), a cycloalkyl, or an aryl (C.sub.6-12)); R and R.sub.1 are independently selected from the group consisting of H, lower alkoxy (C.sub.1-6), and lower alkyl (C.sub.1-6); R.sub.2 is selected from Formula II: ##STR11##wherein X is a halogen, lower alkyl (C.sub.1-6), lower alkoxy (C.sub.1-6), cycloalkyl, cycloalkoxy, aryl (C.sub.6-12)), substituted aryl or hydroxy and n is 0, 1, 2, 3, or 4; anda compound of Formula III: ##STR12##wherein n is 0,1, 2, 3, 4, or 5; M is hydrogen, a salt forming cation, an alkyl (C.sub.1-6), a cycloalkyl, or an aryl (C.sub.6-12); R and R.sub.1 are independently selected from the group consisting of H, lower alkoxy (C.sub.1-6), and lower alkyl (C.sub.1-6); R.sub.2 is selected from Formula II; andwherein the compound of Formula I is present in a 4:1 ratio by mass to the compound of Formula III and the combined concentration of the compound of Formula I and the compound of Formula III is from about 200 mg/mL to about 350 mg/mL, whereby said combined concentration of about 200 mg/mL to about 350 mg/mL; produces increased efficacy for the treatment of neoplastic disease over that achieved by concentrations of about 100 mg/mL.